ABCG2在卵巢黏液性肿瘤中的表达及意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1246 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：研究肿瘤干细胞标志物ABCG2在卵巢黏液性肿瘤中的表达，并探讨其临床意义。方法：采用免疫组织化学PV-9000两步法检测ABCG2在22例卵巢黏液性囊腺瘤、19例卵巢交界性黏液性肿瘤和25例卵巢黏液性囊腺癌中的表达水平，分析其表达情况与卵巢黏液性肿瘤的临床病理特征的关系。结果：ABCG2在卵巢黏液性囊腺瘤、卵巢交界性黏液性肿瘤和卵巢黏液性囊腺癌中的阳性表达率分别为18.2%、47.4%、80.0%，3组间两两比较差异均有统计学意义（P＜0.05）。在卵巢黏液性囊腺癌中，ABCG2在中低分化的阳性表达率高于高分化（P＜0.05），III～IV期高于I～II期（P＜0.05），但其表达与患者年龄无相关性（P＞0.05）。结论：ABCG2可能参与卵巢黏液性肿瘤的发生、发展，其蛋白检测可能用于肿瘤恶性程度的判断。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张乾
	王海欧
	张虎祥
	郑飞云

关键词 ：卵巢黏液性肿瘤, 肿瘤干细胞, ABCG2, 免疫组织化学

Abstract：Objective: To investigate the expression of cancer stem cell marker ABCG2 in ovarian mucinous tumors and its clinical significance. Mehtods: The expression of ABCG2 was detected by immunohistochemical PV-9000 2-step method in 22 cases of ovarian mucinous cystadenoma, 19 cases of ovarian borderline mucinous tumors and 25 cases of ovarian mucinous adenocarcinoma. The relationship between clinicopathologic characteristics was analyzed. Results: The positive expression rate of ABCG2 in ovarian mucinous cystadenoma, ovarian borderline mucinous tumors and ovarian mucinous adenocarcinoma was 18.2%, 47.4% and 80.0%, respectively. The expression level and positive expression rate of ABCG2 in benign mucinous cystadenoma and borderline mucinous tumor, in benign mucinous cystadenoma and mucinous adenocarcinoma, in mucinous borderline tumor and mucinous adenocarcinoma had statistical difference (P<0.05). The expression of ABCG2 in mucinous adenocarcinoma was significantly higher in stage III-IV than that in stage I-II (P<0.05), and it was significantly higher in moderate and poorly differentiated cancer tissues than in well differentiated cancer tissues (P<0.05), but not correlated with patient age (P>0.05). Conclusion: Expression of ABCG2 may participate in ovarian mucinous tumors during the progression from benign to malignant. And the protein detection may have referential significance in the estimation of tumor malignant degree.

Key words： ovarian mucinous tumors cancer stem cell ABCG2 immunohistochemistry

PACS:

基金资助:温州市科技局科研基金资助项目（Y20140113）

通讯作者: 郑飞云，主任医师，Email：zfy5710@163.com

作者简介: 张乾（1980-），男，四川巴中人，主治医师，硕士

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2018/V48/I1/46

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics[J]. CA Cancer J Clin, 2015, 65(1): 5-29.

[2] LIU S, ZHOU J, WEN J, et al. Expression and significance of CD133 and ABCG2 in endometriosis[J]. Clin Exp Obstet Gynecol, 2015, 42(6): 771-775.

[3] GIL J, STEMBALSKA A, PESZ K A, et al. Cancer stem cells: the theory and perspectives in cancer therapy[J]. J Appl Genet, 2008, 49(2): 193-199.

[4] MIRANDA-LORENZO I, DORADO J, LONARDO E, et al.

Intracellular autofluorescence: a biomarker for epithelial cancer stem cells[J]. Nat Methods, 2014, 11(11): 1161-1169.

[5] PISANO C, GREGGI S, TAMBARO R, et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study[J]. Anticancer Res, 2005, 25(5): 3501-3505.

[6] SHIMADA M, KIGAWA J, OHISHI Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary[J]. Gynecol Oncol, 2009, 113(3): 331-334.

[7] AHMED N, A BUBAKER K, FINDLAY J, et al. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance[J]. J Cell Biochem, 2013, 114(1): 21-34.

[8] LI C, LIU B, WEN Z, et al. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo[J]. Folia Biol (Praha), 2008, 54(6): 180-186.

[9] VALEN P, BONNET D, DE MARIA R,et al. Cancer stem cell definitions and terminology: the devil is in the details[J]. Nat Rev Cancer, 2012, 12(11): 767-775.

[10] NATARAJAN K, XIE Y, BAER M R, et al. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance[J]. Biochem Pharmacol, 2012, 83(8): 1084-1103.

[11] GUZEL E, KARATAS O F, DUZ M B, et al. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer[J]. Prostate, 2014, 74(15): 1498-1505.

[12] WANG Y H, LI F, LUO B, et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics[J]. Neoplasma, 2009, 56(5): 371-378.

[13] HANG D, DONG H C, NING T, et al. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma[J]. Dis Esophagus, 2012, 25

(7): 638-644.

[14] LEE S H, KIM H, HWANG J H, et al. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer pa-tients[J]. Pathol Int, 2012, 62(3): 167-175.

[15] SHEN W W, ZENG Z, ZHU W X, et al. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells[J]. J Mol Med (Berl), 2013, 91(8): 989-1000.